Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Posts filed under: Animal Models

Chemokine receptor inhibitors for prevention of cancer metastasis

TweetIn our October 31, 2013 blog article, we discussed recent structural studies of the chemokine receptors CCR5 and CXCR4. We discussed the implications of these studies for the treatment of HIV/AIDS, especially using the CCR5 inhibitor maraviroc (Pfizer’s Selzentry/Celsentri). As discussed in the article, researchers are utilizing the structural studies of CCR5 and CXCR4 to…

Does inflammation in the brain cause aging?

TweetThe Biopharmconsortium Blog has been following novel developments in anti-aging medicine and biology for several years. Much of the interest in this field has centered around sirtuins and potential drugs that modulate these protein deacetylase enzymes. Recently–on May 29, 2013–we published our latest blog article on sirtuins. However, we have long been aware that studies…

Agios Pharmaceuticals files for an IPO

TweetOn June 11, 2013, Agios Pharmaceuticals (Cambridge, MA) filed with the U.S. Securities and Exchange Commission for an Initial Public Offering (IPO). The company plans to raise up to $86 million through this IPO. This news was reported by Fierce Biotech, the Boston Business Journal, and Xconomy, among others. The Biopharmconsortium Blog has been following…

Identification of a novel Alzheimer’s disease pathway provides potential new avenues for drug discovery

Tweet  In August and September of 2012, we published three articles on Alzheimer’s disease on the Biopharmconsortium Blog: New genetics study supports the amyloid hypothesis of Alzheimer’s disease–but the drugs still don’t work! (August 19, 2012.) Here we go again–Lilly’s Alzheimer’s drug solanezumab fails to show efficacy in Phase 3, but company is “encouraged” by…

Alzheimer’s disease–where do we go from here?

Tweet  Our August 19, 2012 and our August 28, 2012 articles on this blog focused on the latest developments in Alzheimer’s disease (AD) drug development. To summarize the conclusions of the articles: The results of a new genetic study by DeCode Genetics and its collaborators strongly support the amyloid hypothesis of AD, and especially the…

Co-clinical mouse/human trials for cancer continue to advance

Tweet  Two previous articles on this blog have included discussions of the “co-clinical mouse/human trial” strategy for improving mouse models of human cancer, and simultaneously improving human clinical trials of drugs for these cancers. Now comes an article on the use of a co-clinical trial strategy in personalized treatment of non-small cell lung cancer (NSCLC)…

How can we fix the clinical trial system?

Tweet  In recent months, there have been quite a few articles on the need to fix the clinical trial system. Among the most recent articles is the one by Boston-based Nature writer Heidi Ledford, Ph.D. published as a News Feature in the 29 September issue of Nature. In my humble opinion, this is the best…

World Drug Targets Summit, Cambridge MA, July 19-21

Tweet  Hanson Wade’s World Drug Targets Summit took place on July 20-21, 2011, with pre-conference workshops on July 19. The conference was held in the Sheraton Commander Hotel in Harvard Square in Cambridge, MA. I led the first workshop on the 19th, on “Developing Improved Animal Models in Oncology and CNS Diseases to Increase Drug…

Update: Workshop on improved animal models for pharma R&D at the World Drug Targets Summit, July 2011

Tweet  The time for the July 2011 World Drug Targets Summit in Cambridge MA is looming closer and closer! Registration for the conference is still open, however. I will lead a workshop entitled “Developing Improved Animal Models in Oncology and CNS Diseases to Increase Drug Discovery and Development Capabilities” at the Summit on July 19. …

Workshop on improved animal models for pharma R&D at the World Drug Targets Summit, July 2011

Tweet  I will lead a workshop entitled “Developing Improved Animal Models in Oncology and CNS Diseases to Increase Drug Discovery and Development Capabilities” at the World Drug Targets Summit in Cambridge MA in July 2011. Workshops will be held on July 19, and the main conference on July 20-21. I am planning to attend the…